Recombinant HIV-1 MN Envelope Glycoprotein gp120 (Baculovirus)

ImmunoDXSKU: 1021

Price:
$595

Description

Product Specifications:

Item# 1021: Recombinant HIV-1 MN Envelope Glycoprotein gp120 (Baculovirus).

 Concentration: See vial 

 Mass/vial: 100ug

 Diluent: PBS  

 Purity:  >95%

 Stabilizer: None

 Preservative: None

 Storage: -75°C

 Physical State: Frozen

 Liquid Stability: At least 24 months at -75°C.

 Applications: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies.

 Description: Gene cloned from T-cell-tropic HIV-1 MN strain and the full length recombinant envelope gp120 glycoprotein produced in the Baculovirus Expression System.

 Purification: This protein is purified by immuno-affinity chromatography to >95% purity as determined by SDS-PAGE, reduced.

 Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and HIV-1 converted human serum polyclonal antibodies in ELISA and Western ELISA.

 Biological Activity: This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells.

 Application and Instructions for use:

Recommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 10-100ng of immobilized protein under standard ELISA conditions.

Related Clinical Trials

 

Official Title: A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

Intervention:

Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN

Group 1: low-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 2: high-dose MN rsgp120/HIV-1 plus QS-21 (13 volunteers). Group 3: AIDSVAX B/E (injection contains each of the two vaccine components, HIV-1 MN rgp120 and A244 rgp120/HIV-1) plus QS-21 plus alum (13 volunteers).

Group 4: high-dose MN rgp120/HIV-1 plus QS-21 plus alum (13 volunteers). Group 5: placebo plus QS-21 (8 volunteers). Volunteers will be closely monitored after each immunization and followed for a minimum of 12 months after the initial immunization.

Payment & Security

American Express Apple Pay Diners Club Discover Elo Google Pay JCB Mastercard Shop Pay Visa

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

Estimate shipping

You may also like